FDA Sets Limits for Controversial Alzheimer Drug, Calls for Investigation

A month after approving a controversial new Alzheimer’s drug, the FDA has signed off on new prescribing instructions to limit its use to only patients with early or mild cases of the disease. The acting head of the FDA, Dr. Janet Woodcock, also announced that she was ordering an investigation into whether the agency acted improperly in approving the medication.